- Report
- November 2021
- 394 Pages
Global
From €3814EUR$4,000USD£3,257GBP
- Report
- October 2021
- 185 Pages
Global
From €3671EUR$3,850USD£3,134GBP
- Report
- April 2024
- 90 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- February 2024
- 104 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- October 2023
- 109 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- October 2023
- 102 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- September 2023
- 95 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- July 2023
- 138 Pages
Global
From €3500EUR$3,933USD£3,093GBP
- Report
- October 2023
- 146 Pages
Global
From €3363EUR$3,528USD£2,872GBP
€3957EUR$4,150USD£3,379GBP
- Report
- May 2022
- 76 Pages
Global
€4529EUR$4,750USD£3,867GBP
- Report
- November 2021
- 302 Pages
Global
From €3337EUR$3,500USD£2,849GBP
- Report
- March 2022
- 175 Pages
Global
From €3399EUR$3,565USD£2,902GBP
- Book
- February 2012
- 216 Pages
- Book
- January 2012
- 464 Pages
- Book
- January 2020
- 504 Pages
- Book
- January 2020
- 504 Pages
The Transdermal Drug market is a subset of the Transdermal and Transmucosal Drug Delivery market. Transdermal drug delivery is a method of delivering drugs through the skin, allowing for systemic absorption of the drug. This method of drug delivery is advantageous because it avoids the first-pass metabolism of the drug, which can reduce the amount of drug available for systemic absorption. Transdermal drug delivery also offers the potential for sustained drug release, allowing for more consistent drug levels in the body.
The Transdermal Drug market is composed of a variety of companies that specialize in the development and manufacture of transdermal drug delivery systems. These companies include 3M Drug Delivery Systems, Acrux, Alza Corporation, BioDelivery Sciences International, Inc., Endo Pharmaceuticals, Inc., and Mylan Pharmaceuticals, Inc. Show Less Read more
